Hsp27 Acts as a Master Molecular Chaperone and Plays an Essential Role in Hepatocellular Carcinoma Progression

Aims: Hsp27, a master molecular chaperone, plays an important role in cancer. However, the specific co-chaperones that partner with Hsp27 and the role of Hsp27 in hepatocellular carcinoma (HCC) are not fully enumerated. The present study focuses on the role of Hsp27 in HCC and explores its potential co-chaperones in HCC development. Methods: Gene overexpression or knockdown was used to observe the role of Hsp27 in HCC. Co-immunoprecipitation and mass spectrometry were used to explore apoptosis resistance by regulating multiple co-chaperones of Hsp27. Hsp27 protein-protein interaction (PPI) networks were constructed by the MetaCore software. Results: Hsp27 was upregulated in HCC tissues, and Hsp27 overexpression significantly facilitated formation of HCC cell colony and invasion in normoxia and tolerance in hypoxia by interacting with HIF-1α. Next, the analysis of microarrays revealed that Hsp27 regulated several cellular signaling pathways, including Wnt, ErbB and TGF-β signaling. Moreover, we characterized the Hsp27 PPI map, which indicated that Hsp27 along with its co-chaperones formed different complexes and exerts transcription regulation activity by activating sp1, c-Myc, p53 and ESR1. Conclusions: Hsp27 along with its co-chaperones was related to the development of HCC by regulating multiple signaling pathways, and drugs that target Hsp27 along with its co-chaperones may be a potential therapy for HCC.

[1]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[2]  Thomas J. Jones,et al.  Primary cilia regulates the directional migration and barrier integrity of endothelial cells through the modulation of Hsp27 dependent actin cytoskeletal organization , 2012, Journal of cellular physiology.

[3]  Haiyang Xie,et al.  NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. , 2011, Cancer letters.

[4]  M. Koch,et al.  Hepatocellular Carcinoma: Current Management and Perspectives for the Future , 2011, Annals of surgery.

[5]  Haiyang Xie,et al.  Overexpression of Long Non-coding RNA HOTAIR Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Following Liver Transplantation , 2011, Annals of Surgical Oncology.

[6]  B. Monsarrat,et al.  Affinity Purification Strategy to Capture Human Endogenous Proteasome Complexes Diversity and to Identify Proteasome-interacting Proteins*S , 2009, Molecular & Cellular Proteomics.

[7]  J. Luk,et al.  Heat shock proteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy. , 2009, Protein and peptide letters.

[8]  M. D. Gao,et al.  Regulation of HSP27 on NF-κB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis , 2009, BMC Cancer.

[9]  Rajagopal N. Aravalli,et al.  Molecular mechanisms of hepatocellular carcinoma , 2008, Hepatology.

[10]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[11]  Jian Wang,et al.  PRINCESS, a Protein Interaction Confidence Evaluation System with Multiple Data Sources*S , 2008, Molecular & Cellular Proteomics.

[12]  M. Sherman,et al.  Hsp27 modulates p53 signaling and suppresses cellular senescence. , 2007, Cancer research.

[13]  Q. Ye,et al.  Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. , 2007, Journal of hepatology.

[14]  A. Määttä,et al.  Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. , 2007, Biochemical and biophysical research communications.

[15]  M. Sherman,et al.  Molecular chaperones regulate p53 and suppress senescence programs , 2007, FEBS letters.

[16]  T. Liang,et al.  MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation , 2007, Journal of surgical oncology.

[17]  Xun Shen,et al.  Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity , 2007, Clinical Cancer Research.

[18]  H. Gutzeit,et al.  Varying responses of human cells with discrepant p53 activity to ionizing radiation and heat shock exposure , 2007, Cell proliferation.

[19]  H. Hondermarck,et al.  Proteomics Exploration Reveals That Actin Is a Signaling Target of the Kinase Akt* , 2007, Molecular & Cellular Proteomics.

[20]  R. J. Aarons,et al.  Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis , 2006, Neurobiology of Disease.

[21]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[22]  J. Klein,et al.  Heat Shock Protein 27 Controls Apoptosis by Regulating Akt Activation* , 2003, Journal of Biological Chemistry.

[23]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[24]  A. Arrigo,et al.  Actin cytoskeleton and small heat shock proteins: how do they interact? , 2002, Cell stress & chaperones.

[25]  W. D. de Jong,et al.  Translocation of small heat shock proteins to the actin cytoskeleton upon proteasomal inhibition. , 2002, Journal of molecular and cellular cardiology.

[26]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[27]  E. Levin,et al.  Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  C. Anderson,et al.  Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. , 1992, The Journal of biological chemistry.

[29]  Haiyang Xie,et al.  NDRG 1 as a biomarker for metastasis , recurrence and of poor prognosis in hepatocellular carcinoma , 2011 .

[30]  V. Rotter,et al.  Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies , 2011, Cancer Gene Therapy.

[31]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[32]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[33]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[34]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.